- Home
- ANGO vs CCCC Comparison
ANGO vs CCCC Comparison
Compare ANGO & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGO | CCCC |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 404.7M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANGO | CCCC |
|---|---|---|
| Price | $15.30 | $3.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $18.00 | $12.20 |
| AVG Volume (30 Days) | 306.1K | ★ 1.8M |
| Earning Date | 04-02-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | $35,947,000.00 |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.17 | 1.02 |
| 52 Week Low | $9.39 | $1.69 |
| 52 Week High | $16.29 | $5.17 |
Technical Indicators
Market Signals| Indicator | ANGO | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 46.50 | 37.75 |
| Support Level | $14.85 | $3.38 |
| Resistance Level | $16.23 | $3.91 |
| Average True Range (ATR) | 0.51 | 0.17 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 25.00 | 13.82 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.